Beyond Fixed Restriction Time: Adaptive Restricted Mean Survival Time Methods in Clinical Trials
超越固定截断时点:临床试验中的自适应限制平均生存时间方法AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要在临床试验中估计和检验绝对治疗收益,直接涉及治疗效应推断。
超越固定截断时点:临床试验中的自适应限制平均生存时间方法AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Summary Restricted mean survival time offers a compelling nonparametric alternative to hazard ratios for right-censored time-to-event data, particularly when the proportional hazards assumption is violated. By capturing the total event-free time over a specified horizon, it provides an intuitive and clinically meaningful measure of absolute treatment benefit. Nonetheless, selecting the restriction time poses challenges: choosing a small restriction time may overlook late-emerging benefits, while a large one can inflate variance and reduce power, an issue whose impact on the precision of inference is often underappreciated. We propose a novel data-driven, adaptive procedure that identifies the optimal restriction time from a continuous range by maximizing a criterion balancing effect size and estimation precision. Consequently, our procedure is particularly powerful when the pattern of the treatment effect is unknown at the design stage. We provide a rigorous theoretical foundation that accounts for the additional variability introduced by adaptive selection. To address nonregular estimation under the null, we develop two complementary strategies: a convex-hull-based estimator, and a penalized approach that regularizes restriction-time selection. Additionally, when restriction time candidates are pre-specified on a discrete grid, our procedure has the same first-order distribution as an oracle estimator evaluated at the penalized population optimizer, with no additional first-order variance from selection. Extensive simulations across realistic survival scenarios demonstrate that our method outperforms traditional restricted mean survival time analyses and the log-rank test, achieving superior power while maintaining approximately nominal type I error rates. In a phase III pancreatic cancer trial with transient treatment effects, our procedure uncovers clinically meaningful benefits that standard methods overlook. Software implementing the methods is available in the package AdaRMST.